HUAXIN CEMENT(06655)
Search documents
华新水泥涨2.01%,成交额2.45亿元,主力资金净流入1014.56万元

Xin Lang Cai Jing· 2025-09-09 03:16
Core Viewpoint - Huanxin Cement's stock price has shown significant growth this year, with a year-to-date increase of 43.81% and a recent surge in trading activity, indicating strong investor interest and market performance [1][2]. Company Overview - Huanxin Cement Co., Ltd. is located in Wuhan, Hubei Province, and was established on November 30, 1993, with its stock listed on January 3, 1994. The company primarily engages in the manufacturing and sales of cement, concrete, aggregates, and other building materials, as well as providing related technical services [2]. - The revenue composition of Huanxin Cement includes cement (52.69%), concrete (24.59%), aggregates (16.49%), other products (4.00%), and clinker (2.22%) [2]. Financial Performance - For the first half of 2025, Huanxin Cement reported operating revenue of 16.047 billion yuan, a year-on-year decrease of 1.17%, while the net profit attributable to shareholders increased by 51.05% to 1.103 billion yuan [2]. - The company has distributed a total of 13.594 billion yuan in dividends since its A-share listing, with 3.127 billion yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, Huanxin Cement had 45,700 shareholders, an increase of 6.56% from the previous period. The average number of circulating shares per shareholder remained unchanged at 0 [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 56.9032 million shares, a decrease of 6.6314 million shares from the previous period, while Southern CSI 500 ETF is a new entrant with 9.995 million shares [3].
副总裁刘凤山增持华新水泥(06655)5.37万股 每股作价13.89港元

智通财经网· 2025-09-08 11:25
Group 1 - The Vice President of the company, Liu Fengshan, increased his holdings in Huaxin Cement (06655) by 53,700 shares at a price of HKD 13.89 per share, totaling approximately HKD 745,900 [1] - After the purchase, the total number of shares held by Liu Fengshan is 345,800, representing a holding percentage of 0.05% [1]
副总裁刘凤山增持华新水泥5.37万股 每股作价13.89港元

Zhi Tong Cai Jing· 2025-09-08 11:22
香港联交所最新资料显示,9月8日,副总裁刘凤山增持华新水泥(600801)(06655)5.37万股,每股作价 为13.89港元,总金额约为74.59万港元。增持后最新持股数目为34.58万股,最新持股比例为0.05%。 ...
工会主席明进华增持华新水泥2.3万股 每股作价13.87港元

Zhi Tong Cai Jing· 2025-09-08 11:22
Group 1 - The union chairman, Ming Jinhua, increased his stake in Huaxin Cement (600801)(06655) by purchasing 23,000 shares at a price of HKD 13.87 per share, totaling approximately HKD 319,000 [1] - After the purchase, the latest number of shares held by Ming Jinhua is 189,300, representing a holding percentage of 0.03% [1]
工会主席明进华增持华新水泥(06655)2.3万股 每股作价13.87港元

智通财经网· 2025-09-08 11:18
智通财经APP获悉,据香港联交所最新数据显示,9月8日,工会主席明进华增持华新水泥(06655)2.3万 股,每股作价13.87港元,总金额约为31.9万港元。增持后最新持股数目为18.93万股,持股比例为 0.03%。 ...
水泥板块9月8日涨0.65%,华新水泥领涨,主力资金净流出2.48亿元

Zheng Xing Xing Ye Ri Bao· 2025-09-08 08:53
证券之星消息,9月8日水泥板块较上一交易日上涨0.65%,华新水泥领涨。当日上证指数报收于 3826.84,上涨0.38%。深证成指报收于12666.84,上涨0.61%。水泥板块个股涨跌见下表: | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600801 | 华新水泥 | 16.41 | 3.27% | 36.11万 | 5.89亿 | | 605122 | 四方新材 | 13.97 | 2.95% | 3.90万 | 5381.15万 | | 603616 | 韩建河山 | 5.63 | 1.99% | 14.42万 | 8045.06万 | | 000672 | 上峰水泥 | 8.80 | 1.97% | 10.86万 | 9494.77万 | | 002205 | 国统股份 | 13.01 | 1.56% | 5.49万 | 7069.19万 | | 600585 | 海螺水泥 | 24.12 | 1.47% | 36.10万 | 8.69亿 | | 002671 | 龙泉股份 | 4 ...
华新水泥(600801):海外延续景气,期待尼日利亚项目带来高弹性
Changjiang Securities· 2025-09-05 05:14
Investment Rating - The investment rating for the company is "Buy" and is maintained [8] Core Views - The company reported a revenue of 16.047 billion yuan in H1 2025, a year-on-year decrease of 1.17%, while the net profit attributable to shareholders was 1.103 billion yuan, showing a significant year-on-year increase of 51.05% [2][4] - In Q2 2025, the revenue was 8.885 billion yuan, down 2.94% year-on-year, but the net profit increased by 57.22% to 870 million yuan [2][4] - The cement gross margin improved, while aggregate sales declined. H1 2025 cement and clinker sales were 27.737 million tons, down 2.6% year-on-year, with overseas sales increasing by 10.4% to 8.388 million tons [5][6] - The company expects the Nigerian project to bring high elasticity to its performance, with anticipated earnings of 3 billion yuan and 3.6 billion yuan for 2025 and 2026, respectively, corresponding to a PE ratio of 11 and 9 times [11] Financial Performance Summary - H1 2025 cement revenue was 9.15 billion yuan, up 5.6% year-on-year, with domestic cement revenue at 5.02 billion yuan, down 1.26%, and overseas cement revenue at 4.128 billion yuan, up 15.37% [5][6] - The overall gross margin increased by 5.3 percentage points to 23.65% compared to the same period last year, driven by higher domestic cement prices and lower costs [6] - The company’s EBITDA from non-cement businesses accounted for 44% of total profits, indicating diversification in revenue streams [6] Regional Performance - Revenue from the African region was 2.136 billion yuan, up 21.51% year-on-year, while the Asian region's revenue was 2.204 billion yuan, up 12.14% year-on-year [11] - The company has initiated several overseas technical transformation projects, including upgrades in Zimbabwe, Zambia, and South Africa, enhancing production capacity [11]
智通港股股东权益披露|9月5日

智通财经网· 2025-09-05 00:09
Group 1 - The latest shareholder equity disclosure for Stone Four Pharmaceutical Group (02005) and Huaxin Cement (06655) was conducted on September 5, 2025 [1] - China Pharmaceutical Company Limited increased its holdings in Stone Four Pharmaceutical Group from 878 million shares to 879 million shares, representing a holding percentage change from 29.74% to 29.77% [2] - Qu Jiguang increased his holdings in Stone Four Pharmaceutical Group from 1.169 billion shares to 1.170 billion shares, with a holding percentage change from 39.61% to 39.64% [2] Group 2 - Liu Weisheng acquired 20,000 shares in Huaxin Cement, changing his holding from 0 shares to 20,000 shares, resulting in a holding percentage of 0% [2]
智通港股股东权益披露|9月3日


智通财经网· 2025-09-03 00:07
Group 1 - The latest shareholder equity disclosures for three companies: Vanguard Medical Biotechnology (00399), Huaxin Cement (06655), and CSPC Pharmaceutical Group (01093) were made on September 3, 2025 [1] Group 2 - Vanguard Medical Biotechnology: - Shareholder Mao Yumin reduced holdings from 1.55 billion shares to 1.50 billion shares, holding percentage decreased from 72.33% to 70.00% [2] - Huaxin Cement: - Shareholder Li Yeqing increased holdings from 454,000 shares to 508,600 shares, holding percentage increased from 0.03% to 0.04% [2] - CSPC Pharmaceutical Group: - Shareholder Cai Xin increased holdings from 50,000 shares to 100,000 shares, holding percentage remained at 0% [2]
华新水泥(600801):盈利能力同比改善 归母净利润同比高增 海外业务持续推进
Ge Long Hui· 2025-09-02 11:55
Core Viewpoint - The company reported a mixed performance in its 2025 H1 financial results, with a slight decline in revenue but a significant increase in net profit, driven by higher average selling prices in the cement business and growth in overseas operations [1][2][3]. Financial Performance - In 2025 H1, the company achieved revenue of 160.47 billion yuan, a year-on-year decrease of 1.17%, while net profit attributable to shareholders reached 11.03 billion yuan, up 51.05% year-on-year [1][2]. - The cement business generated revenue of 91.52 billion yuan in 2025 H1, reflecting a year-on-year increase of 5.60%, with sales volume at 27.74 million tons, down 2.63% year-on-year [2]. - The average selling price of cement was approximately 330 yuan per ton, an increase of 26 yuan per ton year-on-year, while production costs decreased by 9 yuan per ton to 232 yuan [2]. Overseas Business Growth - The overseas cement business reported revenue of 41.28 billion yuan in 2025 H1, a year-on-year increase of 15.37%, accounting for about 25.37% of total revenue [3]. - The company achieved net profit of 5.88 billion yuan from overseas operations, up 17.1% year-on-year, with sales volume of approximately 8.39 million tons, an increase of 10.41% year-on-year [3]. - Significant projects included the upgrade of production lines in Zambia and South Africa, and the acquisition of a 100% stake in a Brazilian aggregate company [3]. Aggregate and Concrete Business - The aggregate business generated revenue of 27.63 billion yuan in 2025 H1, a year-on-year decrease of 6.72%, with sales volume of 76.05 million tons, up 6.33% year-on-year [4]. - The concrete business reported revenue of 34.57 billion yuan, down 12.33% year-on-year, with sales volume of 1.325 million cubic meters, a decline of 9.88% year-on-year [4]. Profitability Metrics - The overall gross profit margin improved to 28.92%, an increase of 5.27 percentage points year-on-year, with the cement business gross margin at 29.74%, up 9.03 percentage points [5]. - The company’s operating cash flow was approximately 16.24 billion yuan, a decrease of 6.17% year-on-year [5]. Strategic Developments - The company announced plans to integrate all overseas assets into a subsidiary intended for overseas listing, focusing on cement manufacturing, sales, and related services [6]. - This strategic move aims to enhance financing capabilities and improve competitiveness in the global cement market [6]. Future Outlook - The company expects continued growth in overseas revenue and performance contributions, supported by an integrated strategy and high-margin aggregate business [7]. - Revenue projections for 2025-2027 are estimated at 360.27 billion yuan, 393.43 billion yuan, and 428.37 billion yuan, with corresponding net profits of 27.20 billion yuan, 30.90 billion yuan, and 34.49 billion yuan [7].